Back to Research Hub
Intellia Therapeutics, Inc.
NTLA
$11.13-0.34 (-2.96%)
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs.
StreetsValue research for Intellia Therapeutics, Inc. (NTLA)
Members get the full report for Intellia Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.